Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Change in Account Payables: 2020-2025

Historic Change in Account Payables for Tango Therapeutics (TNGX) over the last 6 years, with Sep 2025 value amounting to -$344,000.

  • Tango Therapeutics' Change in Account Payables fell 111.29% to -$344,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 million, marking a year-over-year decrease of 270.12%. This contributed to the annual value of -$1.2 million for FY2024, which is 30.56% up from last year.
  • As of Q3 2025, Tango Therapeutics' Change in Account Payables stood at -$344,000, which was up 60.91% from -$880,000 recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Change in Account Payables ranged from a high of $4.5 million in Q3 2022 and a low of -$2.8 million during Q2 2024.
  • Over the past 3 years, Tango Therapeutics' median Change in Account Payables value was -$344,000 (recorded in 2025), while the average stood at -$225,727.
  • Data for Tango Therapeutics' Change in Account Payables shows a peak YoY increase of 43,536.36% (in 2021) and a maximum YoY decrease of 36,537.56% (in 2021) over the last 5 years.
  • Tango Therapeutics' Change in Account Payables (Quarterly) stood at $365,000 in 2021, then slumped by 384.93% to -$1.0 million in 2022, then spiked by 91.54% to -$88,000 in 2023, then crashed by 2,748.86% to -$2.5 million in 2024, then tumbled by 111.29% to -$344,000 in 2025.
  • Its Change in Account Payables stands at -$344,000 for Q3 2025, versus -$880,000 for Q2 2025 and $1.6 million for Q1 2025.